Abstract: Contrary to previous reports, azithromycin has now been associated with arrythmias and sudden cardiac deaths. There is a need for careful consideration of these risk factors with this drug especially when prescribing for the elderly. A more thorough screening of cardiovascular risk prior to starting azithromycin may also be warranted.
INTRODUCTION
Azithromycin has been shown to be an effective treatment for several common dermatological problems, including skin infections, acne, and rosacea. Azithromycin had been reported to be relatively free of cardiotoxic effects, unlike related macrolides erythromycin and clarithromycin, which have been shown to increase the risk for ventricular arrhythmias and sudden cardiac death. Several reports of potential proarrythmic effects of azithromycin spurred further investigation. Recent findings published in the New England Journal of Medicine prompt careful consideration of the necessity for treatment with azithromycin, particularly in patients with a high baseline risk of cardiovascular disease.
Ray et al. [1] did not differ significantly from levofloxacin, which has known arrhythmic potential. The authors concluded that azithromycin use is associated with a small absolute increase in cardiovascular deaths, particularly in patients with a high baseline risk of cardiovascular disease [1] .
Given the widespread use of azithromycin, a relative amount of correspondence followed this noteworthy study [2] . Several writers suggest that confounding cannot be completely resolved given the retrospective nature of the study. For instance, patient characteristics not assessed in the study and indication for antibiotic use might contribute to the increased risk of cardiovascular death. The authors counter that careful statistical analysis was utilized to control these factors, and that in particular, the indications for azithromycin and amoxicillin were similar (primarily for minor ear, nose, or throat infections and respiratory infections). In addition, two correspondence letters describe randomized, placebo-controlled trials that did not demonstrate an increased risk of cardiovascular death. Two such studies involving 11,759 patients with stable coronary artery disease showed no increase in mortality with 600 mg of weekly azithromycin for 3 or 12 months [3, 4] . A third randomized, placebo-controlled trial involving 1,142 participants with chronic obstructive pulmonary disease (COPD) showed that daily azithromycin's use for 1 year reduced the risk of acute exacerbations of COPD [5] . This study did not demonstrate prolonged corrected QT interval (QTc), increases in death, or adverse cardiac events. However, 6% of candidates were excluded from the study for having a QTc interval greater than 450 msec, taking medications that prolong the QTc interval, for having a resting heart rate greater than 100 beats per minute, or for having a history of hypokalemia, congestive heart failure, or a family history of prolonged QTc interval. Furthermore, 10 patients were withdrawn from the study one month after randomization for prolonged QTc interval. The authors counter these 3 randomized, controlled studies by demonstrating that there was significantly less azithromycin exposure, totaling 955 person-years in all 3 studies, than the 4764 person-years in their retrospective study. Furthermore, the authors in the third randomized, controlled study described carefully excluded patients who might be susceptible to the proarrythmic effects of azithromycin [2] .
